Earnings summaries and quarterly performance for Equillium.
Executive leadership at Equillium.
Board of directors at Equillium.
Research analysts covering Equillium.
Recent press releases and 8-K filings for EQ.
Equillium Provides Update on EQ504 Development and Financing
EQ
Guidance Update
New Projects/Investments
- Equillium's lead asset, EQ504, is a differentiated, selective oral aryl hydrocarbon receptor (AhR) modulator with colon-specific delivery, designed to treat ulcerative colitis by addressing immune dysregulation, impaired barrier function, and lack of mucosal healing.
- The company expects to initiate a Phase 1 SAD/MAD study for EQ504 in healthy volunteers mid-year 2026, likely in Australia, which will include flex sigmoidoscopy to assess tissue exposure and target engagement in the colon.
- Data from the Phase 1 SAD/MAD study is anticipated in the first half of 2027.
- Equillium secured $50 million in financing, with $30 million already received and an additional $20 million to be triggered upon clinical study initiation. This funding is expected to provide a cash runway through the end of 2027 with the initial tranche, extending into the 2027-2028 timeframe with the second tranche, covering the SAD/MAD program and potentially some patient-level data.
Feb 12, 2026, 8:30 PM
Equillium Provides Update on EQ504 Development and Financing
EQ
New Projects/Investments
Guidance Update
- Equillium's lead asset, EQ504, is a differentiated, selective oral aryl hydrocarbon receptor (AhR) modulator with colon-specific delivery, designed to address immune dysregulation, impaired barrier function, and mucosal healing in ulcerative colitis.
- All key IND-enabling studies for EQ504 are complete, and the Phase 1 study in healthy volunteers is expected to commence mid-2026 in Australia, with data anticipated in the first half of 2027.
- The company secured $50 million in financing in August, with $30 million received upfront and a $20 million second tranche contingent on the start of the clinical study.
- Equillium projects its $30 million cash on hand will fund operations towards the end of 2027, with the additional $20 million tranche extending the runway into the 2027-2028 timeframe.
- Beyond ulcerative colitis, EQ504 is being considered for potential expansion into lung indications such as COPD and IPF, and Crohn's disease.
Feb 12, 2026, 8:30 PM
Equillium Reports Q3 2025 Financial Results and Operational Update
EQ
Earnings
Guidance Update
New Projects/Investments
- Equillium reported no revenue for the third quarter of 2025, a decrease from $12.2 million for the same period in 2024, leading to a net loss of $4.2 million (or $(0.06) per basic and diluted share).
- Research and development expenses significantly decreased to $1.3 million in Q3 2025 from $9.6 million in Q3 2024, mainly due to lower clinical development expenses and reduced headcount.
- The company secured financing of up to $50 million, with an initial $30 million tranche expected to fund operations through 2027.
- Equillium plans to initiate the EQ504 Phase 1 clinical study in mid-2026.
Nov 13, 2025, 9:10 PM
Equillium Updates on EQ504 Clinical Development and Financing
EQ
New Projects/Investments
Product Launch
- Equillium is progressing EQ504, an AhR modulator for Ulcerative Colitis, with a Phase 1 study anticipated to begin mid-2026 and topline data expected six months later.
- The company completed an investment of up to $50 million in August 2025, with the initial $30 million tranche extending its financial runway through the end of 2027. A potential second tranche of $20 million could further extend this beyond 2027.
- As of September 30, 2025, Equillium held $33.1 million in cash and equivalents.
- The Ulcerative Colitis market represents a significant opportunity, with ~800,000 patients treated in the U.S. in 2023 and a global market projected to exceed $12 billion by 2030.
Nov 13, 2025, 12:00 PM
Equillium announces leadership changes and pipeline focus shift
EQ
Board Change
Management Change
New Projects/Investments
- Equillium announced Board of Directors and senior leadership changes effective October 1, 2025, and other corporate updates on October 6, 2025.
- Stephen Connelly, Ph.D. was promoted to President in addition to his Chief Scientific Officer role, and Daniel M. Bradbury transitioned from Executive Chairman to Chairman of the Board.
- The company is sharpening its therapeutic pipeline focus on advancing EQ504, a novel aryl hydrocarbon receptor modulator, into the clinic to treat severe inflammatory diseases.
- The collaboration and license agreement with Biocon for itolizumab was terminated on September 30, 2025, as Equillium no longer intends to develop itolizumab.
Oct 6, 2025, 8:02 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more